Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Genetics

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Objective To investigate the neurocognitive measures that best predict progression from amnestic mild cognitive impairment (aMCI) to Alzheimer disease (AD). Methods We evaluated 539 participants with aMCI from the Alzheimer's Disease Cooperative Study clinical drug trial of donepezil, vitamin E, or placebo. During the study period of 36 months, 212 aMCI participants progressed to AD. Using progression from aMCI to AD within 36 months as the dependent variable, a generalized linear model was fit to the data using the least absolute shrinkage and selection operator. Independent variables included in this analysis were age, sex, education, APOE-e4 (APOE4) status, family history of dementia, Mini-Mental State Examination score, Digits Backwards (Wechsler Memory Scale), Maze Time and Errors, Number Cancellation, Delayed Recall of Alzheimer's Disease Assessment Scale Word List, New York University Paragraph Recall Test (Immediate and Delayed), Boston Naming Test, Category Fluency, Clock Drawing Test, and the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-cog). Results The model that best predicted progression from aMCI to AD over 36 months included APOE4 status, the Symbol Digit Modalities Test, Delayed 10-Word List Recall, New York University Paragraph Recall Test (Delayed), and the ADAS-cog total score. When APOE4 was removed from the analysis the resulting model had a similar estimated predictive accuracy as the full model. As determined by cross-validation, the estimated predictive accuracy of the final model was 80%. Conclusion Progression from amnestic mild cognitive impairment to Alzheimer disease in this cohort was best determined by combining four common, easily administered, cognitive measures.

What this study adds

Evidence grade: Moderate

This is a trial of 539 participants. In 539 people with amnestic mild cognitive impairment followed for 36 months in an Alzheimer's Disease Cooperative Study drug trial, 212 progressed to Alzheimer's disease. This is about predicting who progresses, measured within one trial cohort, not about diagnosing an individual or treating, curing or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Fleisher, A. S., Sowell, B. B., Taylor, C., Gamst, A. C., Petersen, R. C., Thal, L. J., et al. (2007). Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology. https://doi.org/10.1212/01.wnl.0000258542.58725.4c

Vancouver

Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ, et al. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology. 2007. doi:10.1212/01.wnl.0000258542.58725.4c. PMID: 17287448.

BibTeX

@article{fleisher2007-17287448,
  author  = {Fleisher, A. S. and Sowell, B. B. and Taylor, C. and Gamst, A. C. and Petersen, R. C. and Thal, L. J. and {Alzheimer's Disease Cooperative Study}},
  title   = {{Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment}},
  journal = {Neurology},
  year    = {2007},
  doi     = {10.1212/01.wnl.0000258542.58725.4c},
  pmid    = {17287448},
  url     = {https://doi.org/10.1212/01.wnl.0000258542.58725.4c}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

In 539 people with amnestic mild cognitive impairment followed for 36 months in an Alzheimer's Disease Cooperative Study drug trial, 212 progressed to Alzheimer's disease. The best prediction came from combining "four common, easily administered, cognitive measures" (delayed word-list and paragraph recall, the Symbol Digit Modalities Test and the ADAS-cog) with APOE4 status, for an estimated 80% cross-validated accuracy, and dropping APOE4 left accuracy "similar". This is about predicting who progresses, measured within one trial cohort, not about diagnosing an individual or treating, curing or preventing Alzheimer's disease.

Study details

How this study scored 69/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 11 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 1 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 69 of 100.69 of 100 points earned31 not earned

Published in a leading specialty journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomized controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2007 — within 20 year(s) of the newest study here
Sample size 2 / 4 539 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited 5 / 7 Cited 234 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 11.1 citations a year over 21 year(s) since 2007
Impact for its field and year 4 / 6 Cited 10.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 17 other studies in this library
Still being cited 2 / 4 Cited 19 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Leon J. Thal: h-index 64 (OpenAlex, whole career)
Institution's track record 2 / 3 University of California San Diego: institution h-index 1,852 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 17287448)
Free to read 0 / 2 Behind a paywall — scores zero
Total 69 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.

Later studies that cite this one

17 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Genetics from nearby years

Also tagged “mini-mental”

840 studies in the library carry the topic tag “mini-mental”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 840 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Genetics

See all studies in Genetics →